These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35743387)

  • 1. Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases.
    Primas C; Reinisch W; Panetta JC; Eser A; Mould DR; Dervieux T
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P010 Precision Dosing Tool Forecasts Trough Infliximab and Associates With Disease Status in Inflammatory Bowel Diseases.
    Dervieux T; Primas C; Panetta J; Mould D; Eser A; Reinisch W
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S3. PubMed ID: 37461930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
    Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
    Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
    Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
    Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
    AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
    Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
    World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.
    Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML
    Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world impact of infliximab precision-guided dosing on management of patients with IBD.
    Abraham BP; Ziring DA; Dervieux T; Han PA; Shim A; Battat R
    Am J Manag Care; 2023 Oct; 29(12 Suppl):S227-S235. PubMed ID: 37844322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.
    Strik AS; Löwenberg M; Mould DR; Berends SE; Ponsioen CI; van den Brande JMH; Jansen JM; Hoekman DR; Brandse JF; Duijvestein M; Gecse KB; de Vries A; Mathôt RA; D'Haens GR
    Scand J Gastroenterol; 2021 Feb; 56(2):145-154. PubMed ID: 33290108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.
    Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.
    Dubinsky MC; Mendiolaza ML; Phan BL; Moran HR; Tse SS; Mould DR
    Inflamm Bowel Dis; 2022 Sep; 28(9):1375-1385. PubMed ID: 34978325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
    Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
    Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
    Grinman AB; de Souza MDGC; Bouskela E; Carvalho ATP; de Souza HSP
    Medicine (Baltimore); 2020 Mar; 99(10):e19359. PubMed ID: 32150077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management.
    Grisic AM; Eser A; Huisinga W; Reinisch W; Kloft C
    Br J Clin Pharmacol; 2021 May; 87(5):2374-2384. PubMed ID: 33184852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
    Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
    Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab in young paediatric IBD patients: it is all about the dosing.
    Jongsma MME; Winter DA; Huynh HQ; Norsa L; Hussey S; Kolho KL; Bronsky J; Assa A; Cohen S; Lev-Tzion R; Van Biervliet S; Rizopoulos D; de Meij TGJ; Shouval DS; Wine E; Wolters VM; Martinez-Vinson C; de Ridder L;
    Eur J Pediatr; 2020 Dec; 179(12):1935-1944. PubMed ID: 32813123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
    Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA
    Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.